Capital World Investors
CRSP icon

Capital World Investors’s CRISPR Therapeutics CRSP Stock Holding History

Capital World Investors’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$259M Buy
4,749,525
+24,488
+0.5% +$1.29M 0.03% 293
2026
Q1 		$225M Buy
+4,725,037
New +$249M 0.03% 291
2022
Q1 		– Sell
-421,486
Closed -$31.9M – 593
2021
Q4 		$31.9M Buy
+421,486
New +$36.8M 0.01% 491
2018
Q3 		– Sell
-138,000
Closed -$8.11M – 560
2018
Q2 		$8.11M Hold
138,000
– – ﹤0.01% 505
2018
Q1 		$6.31M Buy
+138,000
New +$5.7M ﹤0.01% 492

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors's CRSP Position: Q2 2026 in Review

Capital World Investors increased its CRISPR Therapeutics (CRSP) stake by 0.52% in Q2 2026, buying an estimated $1.29M and bringing the position to 4,749,525 shares worth $259M. The position accounts for 0.03% of the portfolio, ranked #293.

Capital World Investors first reported a position in CRSP in Q1 2018 and has held it in 5 quarters since. 521 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Capital World Investors held 4,749,525 shares of CRISPR Therapeutics worth $259M as of Q2 2026.
  • Capital World Investors bought 24,488 CRISPR Therapeutics shares in Q2 2026, an estimated $1.29M.
  • CRISPR Therapeutics made up 0.03% of Capital World Investors's portfolio in Q2 2026, its #293 holding.
  • Capital World Investors first reported a position in CRISPR Therapeutics in Q1 2018 and has held it in 5 quarters since.
  • 521 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Capital World Investors's 13F filing for Q2 2026, filed 12 Aug 2026.